Figure_5.tif (902.95 kB)

Effects of LY2603618 on the cytotoxicities of cisplatin, doxorubicin, or etoposide in SK-N-BE(2) cells.

Download (0 kB)
figure
posted on 30.09.2013, 03:02 by Guan Wang, Holly Edwards, J. Timothy Caldwell, Steven A. Buck, William Y. Qing, Jeffrey W. Taub, Yubin Ge, Zhihong Wang

Panel A: SK-N-BE(2) cells were treated with variable concentrations of LY2603618 for 48 h and cell viabilities were determined by MTT assays. The data are presented as means ± standard errors from three independent experiments. Panel B: SK-N-BE(2) cells treated with variable concentrations of LY2603618 for 48 h were harvested and subjected to Western blots probed by anti-CF-Casp3, -PARP, -CHK1, -p-CDC25CS216, -CDK1, -p-CDK1Y15, or –β-actin antibody. Panels C-F: The SK-N-BE(2) cells were treated with etoposide, doxorubicin, or cisplatin for 48 h in the absence or presence of 8 µM LY2603618 administered simultaneously. Cell death was determined by trypan blue exclusion (panel C), while apoptosis and cell cycle progression were determined by PI staining and flow cytometry analyses (panels D and E). Soluble proteins were subjected to Western blots probed by anti-CF-Casp3, -PARP, -CHK1, -p-CDC25CS216, -CDK1, -p-CDK1Y15, or -β-actin antibody (panel F). The trypan blue exclusion data are presented as means ± standard errors from three independent experiments, while the PI staining and flow cytometry analysis experiment was repeated two times and the data are presented as means of triplicates from one representative experiment. * indicate p<0.05. LY, LY2603618.

History

Licence

Exports

Logo branding

Categories

Licence

Exports